Published in AIDS Weekly, February 1st, 1999
Researchers from Italy's University of Palermo investigated the antitumor effects of 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a]benzimidazole (TBZ), a new anti-HIV-1 agent, on human promyelocytic HL60 leukemia, in both a parental and a multidrug resistant form (HL60R).
"HL60R overexpresses P-glycoprotein and, like HL60, lacks p53 protein expression. HL60 and HL60R show similar levels of Bcl-2 protein," S. Grimaudo and colleagues wrote ("Selective Induction of Apoptosis in Multidrug Resistant HL60R Cells by the Thiazolobenzoimidazole Derivative 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a]...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.